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EFFECT OF ANDROGEN SUPPRESSION ON BONE MINERAL 
DENSITY IN PATIENTS WITH PROSTATE CANCER
O.A. Chernichenko1, *, V.S. Sakalo1, P.G. Yakovlev2, A.V. Sakalo1, Y.V. Zhylchuk1, A. Zsolt3
1SE “Intitute of Urology of National Academy of Medical Sciences”, Kyiv 04053, Ukraine
2Uzhgorod Central City Clinical Hospital, Uzhgorod 88000, Ukraine
3Debrecen University Clinic, Nagyerdei körút 98, Debrecen 4012, Hungary
The androgen-suppressive therapy (AST) in patients with prostate cancer (PC) may dramatically affect the bone mineral density 
(BMD), which puts patients at risk of severe adverse effects, such as weight-bearing bone fractures. Aim: To study the effect of AST 
on BMD in patients with non-metastatic hormone-sensitive PC treated with intermittent hormonal therapy, and effect of different 
total testosterone level on BMD. Materials and Methods: From 2011 to 2013 we treated 56 patients with non-metastatic hormone-
naïve PC. Intermittent hormonal treatment with flutamide at a dose of 250 mg 3 times per day with nine monthly injections 
of luteinizing gonadotropic releasing hormone (LGnRH) [“treatment” period] followed by period of observance (“no treatment”) 
was administered. We evaluated the BMD of lumbar spine and both proximal thighs by means of dual-energy x-ray densitometry 
at the end of “treatment” period and at the end of “no treatment” period. Results: During the first treatment period, 44 of 56 pa-
tients (78.6%) experienced the reduction in BMD in both lumbar spine and thighs. Total testosterone level in all patients dropped 
to castration level. During the first period of “no treatment” there was an increase in BMD (p < 0.05) in 30 (68.2%) of 44 patients. 
The median time to recovery of total testosterone level to the level > 50 ng/dl was 91 days (from 30 to 308 days), and > 100  ng/dl was 
110 days (from 49 to 343 days). The changes in BMD positively correlated with the changes in total testosterone level (correlation 
0.18 [95% CI, 0.04–0.27], p = 0.009). The decline in total testosterone level in serum was followed by the decline in BMD value 
in the studied areas, and vice versa. Conclusions: The changes in BMD positively correlated with changes in total testosterone 
level. The BMD decreases during the androgen suppression and increases during the pause in the treatment. This demonstrates 
the benefit of intermittent AST in preventing osteoporosis, pathological bone fractures and possibly, bone metastases.
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Androgen-suppressive therapy (AST), which 
is achieved by performing bilateral orchiectomy, ad-
ministration of agonists or antagonists of luteinizing 
gonadotropic releasing hormone (LGnRH) is widely 
used in the treatment of prostate cancer (PC) [1]. 
Long-term AST may cause side effects, such as hot 
flashes, sexual dysfunction, hyperlipidemia, increased 
risk of heart attack, etc. [2, 3]. AST may also lead to re-
duction in bone mineral density (BMD), which incre-
ases the risk of osteoporosis and bone fractures [4]. 
Admission of AST longer than 1 year increases 
the rate of BMD loss by 5–10 times and, consequently, 
the risk of fractures [5]. The efficacy of intermittent 
AST compared with continuous AST showed similar 
results in cancer-specific and overall survivals [6, 7]. 
Intermittent AST reduces the frequency of hot flashes 
and erectile dysfunctions, but lacks the data about 
the impact on BMD and fracture prevention [8].
We explored short-term changes in BMD over 
the course of intermittent AST in men with nonmeta-
static hormone-sensitive PC.
MATERIALS AND METHODS
During November 2011 to December 2013 we trea-
ted 56 patients with non-metastatic hormone-sensi-
tive PC. All patients were administered intermittent 
AST. The patients were classified as per D’Amico [9] 
as PC patients with mild to moderate risk of progres-
sion (total prostate-specific antigen [PSA] < 20 ng/ml, 
the Gleason score ≤ 7). The study was approved 
by the Bioethics Committee of SE “Institute of Urology 
of National Academy of Medical Sciences of Ukraine”. 
All patients signed informed consent to participate 
in the study. The study group also included patients 
with biochemical recurrence of PC after radical pros-
tatectomy or external beam radiation therapy (EBRT). 
The level of PSA was determined in serum by enzyme 
immunoassay test. All patients underwent bone scan 
(BS), computed tomography (CT) of chest, abdomen 
and pelvis, and bone densitometry by means of dual-
energy x-ray absorbtiometry (DEXA). The metastatic 
disease was ruled out by BS and CT. The BMD was 
determined on DEXA by scanning the lumbar spine 
and both proximal thighs using densitometer “Prodigy” 
GE, Lunar. The study included measurement of two 
variables: 1. Projected square of the investigated 
area, in cm2 (area). 2. Bone mineral content of the 
given square, in g (BMD). The clinically important 
parameter projected BMD (BMD/area) was calculated 
using these two values and was expressed in g/cm2. 
The degree of reduction in BMD was assessed by the 
 T-score according to the WHO classification [10]. 
T-score is the difference between the bone density 
of a particular patient and the mean density of young 
healthy adult in the age prior to the loss of bone den-
sity in people of the same sex. Results are expressed 
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in standard deviations (SD). Normal BMD is within one 
SD of the young adult mean (T > −1.0). Decreased bone 
density (osteopenia) is observed at the value of BMD 
between −1.0 and −2.5 SD [T — (−1.0)–(−2.5)]. A DEXA 
T-score less than or equel to −2,5 SD from the mean 
peak bone mass (T — ≤ −2.5) is considered osteopo-
rosis. Using the DEXA results all patients were split into 
groups with osteopenia and osteoporosis according 
to decreased T-score in at least one of the examined 
 areas of the skeleton (lumbar spine, both proximal 
thighs) as per appropriate standards of WHO [10].
The patients were administered 9 months of AST 
(flutamide + LGnRH). After 9 months of the treat-
ment BS, CT and DEXA were done. AST was stopped 
when reached the PSA nadir of ≤ 4 ng/ml. When PSA 
value was enhanced above predetermined threshold 
(PSA > 1 ng/ml for patients after radical prostatectomy, 
and PSA > 4 ng/ml for patients after EBRT or AST 
monotherapy), we administered new course of hor-
monal treatment and repeated the baseline assess-
ments. We measured PSA total and total testosterone 
monthly. Each cycle of therapy included 9-months 
period of hormonal treatment followed by variable 
period of “no treatment”, length of which depended 
on the growth of PSA above the predetermined thresh-
old. All patients were on AST until the signs of hormonal 
resistance, which was defined by three consecutive 
increases in PSA when the total testosterone level was 
at the castrate level (< 20 ng/dl) (Fig. 1).
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Fig. 1. The full cycle of intermittent AST
The absolute change and percentage change 
of initial average BMD compared with subsequent 
DEXA measurements were estimated in patients during 
“treatment” and “no treatment” periods. The correla-
tion between BMD and total testosterone level was 
evaluated with use of Pearson correlation coefficient.
RESULTS
The mean age of patients was 64.5 years (from 
49.8 to 80.9 years). Depending on the type of treat-
ment received, all patients were split in the following 
groups: AST monotherapy — 40 patients, adjuvant 
AST after EBRT — 13 patients, adjuvant AST after 
radical prostatectomy — 3 patients. The patients were 
divided into following groups according to BMD values 
of T-score: T > 2.5 — 3 patients, T-score = 1.0–2.5 — 
18 patients, T-score = 0.0–1.0 — 35 patients, T-score 
= (−1.0)–0.0 — 16 patients, T-score = (−2,5)–(−1,0) — 
11 patients (Table).
Table. Initial BMD (T-score)
TSD > 2.5 1.0–2.5 0.0–1.0 –1.0–0.0 –2.5–(–1.0)
Number of patients 3 18 35 16 11
The average initial BMD T-score was −0.02 (from 
−2.48 to 4.64). There were two AST cycles completed 
during the study (see Fig. 1). After the first 9 months 
of AST average absolute difference of BMD was 
−0.04 g/cm² (p < 0.001). The average relative dif-
ference in BMD after the first treatment period was 
−3.4% (p < 0.001). After the first period of the “no treat-
ment” average absolute difference of BMD was 
0.02 g/cm2 (p = 0.001). The average relative difference 
of BMD after the first “no treatment” period was 1.4% 
(p < 0.001). Thus, the increase in BMD was statisti-
cally significant after the first period of “no treatment”.
During the first treatment period the decrease in BMD 
was observed in 44 (78.5%) of 56 patients. During the first 
“no treatment” period BMD grew in the examined bone 
areas (p < 0.05) in 30 (66.7%) of 45 patients (Fig. 2).
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Fig. 2. Patients with types of BMD’s violations during the treatment
38 (67.85%) among 56 patients had an initial 
 average BMD within the normal range. 5 (13.15%) men 
out of 38 developed the secondary osteopenia du-
ring the treatment. The primary osteopenia was seen 
in 17 (30.35%) of 56 patients at the baseline. BMD 
returned to normal values in 4 (23.5%) of 17 patients 
with primary osteopenia during no AST treatment. Only 
1 (1.8%) patient of 56 had primary osteoporosis. There 
was no pathological fractures occurred among patients 
who received intermittent AST over 2 years.
The median time to recovery of the total tes-
tosterone levels greater than 50 ng/dl was 91 days 
(from 30 to 308 days), and to the level greater than 
100 ng/dl was 110 days (from 49 to 343 days). Only 
in 6 patients (13.3%) the total testosterone level re-
mained stable at the castrate level during “no treat-
ment” period. In the rest, total testosterone level 
was  100 ng/dl during “no treatment” period. Thus, 
the production of total testosterone was restored du-
ring the periods between AST in the most patients. 
The changes in BMD positively correlated with chan-
ges in total testosterone level (correlation 0.18 [95% 
CI, 0.04–0.27], p = 0.009), which means that the in-
crease of total serum testosterone level was followed 
by the increase in BMD value in the studied areas and 
vice versa.
DISCUSSION
In this study we presented the dynamics of changes 
in BMD during intermittent AST. DEXA was performed 
at the beginning of each treatment period and at the pe-
riod of “no treatment”. This let us assess the effects 
of decline and growth of testosterone level on BMD 
values. There was no evidence of pathological frac-
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tures occurred among patients receiving intermittent 
AST over 2 years. In patients who received continuous 
AST, the incidence of fractures accounted for 3.9% 
over 2 years [11]. This study showed that BMD was 
decreased during the hormonal therapy and increased 
during recovery of testosterone level during “no treat-
ment” period. To maintain stable BMD in men receiving 
AST, and to improve BMD in patients with secondary 
reduction of BMD an antiresorptive therapy may be pre-
cribed: bisphosphonates, inhibitor of RANK ligand 
(denosumab), anti-estrogenic drugs (toremifene), 
calcitonin and more [12]. Intermittent AST promotes 
recovery of BMD in the period of withdrawal of hormonal 
treatment, which may prevent the appearance of os-
teoporosis and prevent the administration of additional 
therapy. That’s why in our study the patients were not 
prescribed any antiresorptive medication.
Yi et al. [13] have shown in an animal model of os-
teoblastic metastasis that an initial phase of bone 
destruction is followed by extensive formation of bone. 
Their data suggest that bone resorption precedes 
bone formation in the development of osteoblastic 
metastases and that osteoclast activation plays 
an important role in the development of osteoblastic 
metastases. The production of testosterone is shut 
with continuous AST, which causes the decrease 
in osteoprotegerin receptor expression, and its lack 
accelerates bone resorption through the complex 
cellular mechanisms [14]. Thus, it can be postulated 
that intermittent AST delays the appearance of bone 
metastases due to the decrease in resorptive pro-
cesses in skeleton.
In conclusion, we have shown that the changes 
in BMD positively correlated with changes in total 
testosterone level. The BMD decreases during the an-
drogen suppression and increases during the pause 
in the treatment. This demonstrates the benefit of inter-
mittent AST for the prevention of osteoporosis, patho-
logical bone fractures, and, possibly, development 
of bone metastases.
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